Skip to main content

Table 5 Association between genotypes and median (EFS) rate in osteosarcoma patients treated with cisplatin combination

From: The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients

Genotypes Median EFS survival rate in years Log rank
ERCC1 118 CC 2.29 0.802
ERCC1 118 CT 1.42
ERCC1 118 TT 1.73
ERCC1 8092 CC 1.42 0.023
ERCC1 8092 CA 2.29
ERCC1 8092 AA 0.24
ERCC2 312 GG 1.42 0.147
ERCC2 312 GA 2.29
ERCC2 312 AA 1.17
ERCC2 751 AA 1.3 0.295
ERCC2 751 AC 2.8
ERCC2 751 CC Not reached